A5101740964- HIV Research and Treatment
- Immunotherapy and Immune Responses
- Herpesvirus Infections and Treatments
- Viral Infections and Outbreaks Research
- Virology and Viral Diseases
- vaccines and immunoinformatics approaches
- Viral Infections and Vectors
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Cancer Research and Treatments
- Immune Cell Function and Interaction
- Ethics and Legal Issues in Pediatric Healthcare
- T-cell and B-cell Immunology
- HIV/AIDS Research and Interventions
- Transgenic Plants and Applications
- Ultrasound and Hyperthermia Applications
- Virus-based gene therapy research
- Viral gastroenteritis research and epidemiology
- RNA Interference and Gene Delivery
- MRI in cancer diagnosis
- HIV/AIDS drug development and treatment
- Global Security and Public Health
- Hepatitis B Virus Studies
- Animal Virus Infections Studies
Profectus Biosciences (United States)
2015-2023
Jiading District Central Hospital
2015
Pearl River Community College
2008
Significance Our candidate HIV vaccine, a single-chain gp120-CD4 chimera, elicits protection against acquisition of simian-human immunodeficiency virus (SHIV)/simian (SIV) in rhesus macaques. Antibody-dependent cellular cytotoxicity was an inverse correlate infection risk. However, it is attenuated when antigen-specific T-cell responses exceed threshold, presumably due to the generation CD4+ CCR5+ T cells, preferred targets SHIV/SIV. Multiple studies strongly suggest that HIV/SIV-specific...
Despite lack of vaccine efficacy, the kinetics and magnitude HIV rebound in early-treated patients affect future clinical trial design.
Background The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. objective this study was test the safety tolerability a novel vaccine regimen incorporating these strategies with different doses IL-12 adjuvant. Methods In phase 1 study, 88 participants received an HIV-1 multiantigen (gag/pol, env, nef/tat/vif) (HIV-MAG, 3000 μg) co-administered adjuvant at...
Previous studies demonstrated that a single intramuscular (i.m.) dose of an attenuated recombinant vesicular stomatitis virus (rVSV) vector (VesiculoVax platform; rVSV-N4CT1) expressing the glycoprotein (GP) from Mayinga strain Zaire ebolavirus (EBOV) protected nonhuman primates (NHPs) lethal challenge with EBOV strains Kikwit and Makona. Here, we studied immunogenicities expanded range rVSV vectors filovirus GP in mice. Based on data those studies, optimal trivalent formulation was...
ABSTRACT The HIV Vaccine Trials Network (HVTN) 087 vaccine trial assessed the effect of increasing doses pIL-12 (interleukin-12 delivered as plasmid DNA) adjuvant on immunogenicity an HIV-1 multiantigen (MAG) DNA by electroporation and boosted with a comprising attenuated vesicular stomatitis virus expressing Gag (VSV-Gag). We randomized 100 healthy adults to receive placebo or 3 mg HIV-MAG (ProfectusVax gag / pol ProfectusVax nef tat vif , env ) coadministered at 0, 250, 1,000, 1,500 μg...
Vaccination is a proven intervention against human viral diseases; however, success Herpes Simplex Virus 2 (HSV-2) remains elusive. Most HSV-2 vaccines tested in humans to date contained just one or two immunogens, such as the virion attachment receptor glycoprotein D (gD) and/or envelope fusion protein, B (gB). At least three factors may have contributed failures of subunit-based vaccines. First, immune responses directed antigens lack sufficient antigenic breadth for efficacy. Second,...
Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 have been adopted, including viral platforms such VSV. A major advantage of VSV expressing these that also acts an oncolytic virus, leading direct cell killing induction effective anti-E6 anti-E7 T responses. We shown addition immune adjuvant genes, IFNβ, further enhances safety and/or efficacy...
An effective vaccine for HIV still remains elusive. Our previous studies showed that a protein-based FLSC (a genetic fusion of gp120 and CD4) protected macaques against repeat rectal challenges with SHIV162P3 but efficacy was low. We hypothesized DNA would provide superior prime to subunit boost than alone the adjuvants IL-12 and/or LTA1 improve priming. delivery regimens were evaluated in challenge model using SIVsmE543 antigens cross clade SIVmac251. Eight macaques/group immunized...
A guiding principle for HIV vaccine design has been that cellular and humoral immunity work together to provide the strongest degree of efficacy. However, three efficacy trials Ad5-vectored vaccines showed no protection. Transmission was increased in 2 trials, suggesting this strategy elicited CD4+ T cell responses more targets infection, attenuating protection or increasing transmission. The which problem extends other candidates is not known. Here, we show a gp120-CD4 chimeric subunit...
Antibodies that recognize highly conserved domains on envelope could inhibit HIV infection by direct neutralization or Fc receptor-dependent effector mechanisms including ADCC. The Full Length Single Chain (FLSC) is a gp120-CD4 D1D2 fusion stably expresses transition state structure exposed gp120 after it engages CD4, and antigenically distinct from free the trimeric envelope. This transitional can be defined monoclonal antibodies such as N12-i2 CD4 induced epitopes. We exploited this aspect...
Objective To explore the correlation of contrast-enhanced ultrasound (CEUS) parameters and pathologic parameter renal fibrosis. Methods Thirty-eight healthy New Zealand rabbits were randomly divided into blank control group experimental group. The model was built by intravenous injection C-bovine serum albumin (C-BSA) to According different time points (2, 4, 6 8 weeks) after C-BSA, in 4 sub groups, each We collected data CEUS Moreover, tissues underwent examinations. Then, analysis...